Endothelium-targeted pharmacotherapeutics for the treatment of stroke

Gary Danton, Brant D. Watson, Ricardo Prado, W. Dalton Dietrich

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations


The pathophysiology of stroke in humans is much more complex than what is typically studied in animal models. Embolic stroke models are more complex than pure ischemia models, but are more representative of human disease and may be particularly useful in the study of new therapeutic strategies. Vascular damage is a prominent feature of embolic stroke, and may be a useful therapeutic target. Serotonin antagonists, adenosine-regulating agents, free radical scavengers, matrix metalloproteinase inhibitors, and HMG-CoA reductase inhibitors are all potentially valuable agents in treating vascular damage after stroke. These agents facilitate decreased infarction volume, hemorrhage, and improved cerebral blood flow.

Original languageEnglish (US)
Pages (from-to)896-904
Number of pages9
JournalCurrent Opinion in Investigational Drugs
Issue number6
StatePublished - Jun 1 2002


  • Animal model
  • Cerebrovascular disorder
  • Endothelium
  • Vascular pharmacotherapy

ASJC Scopus subject areas

  • Pharmacology


Dive into the research topics of 'Endothelium-targeted pharmacotherapeutics for the treatment of stroke'. Together they form a unique fingerprint.

Cite this